Association of type 2 diabetes, hypertension, and hyperlipidemia with immune-related adverse events in patients undergoing immune checkpoint inhibitors therapy
Our study is the first to confirm an association between T2DM, hypertension, and hyperlipidemia and the occurrence of irAEs in cancer patients receiving ICIs therapy. This finding highlights the critical need for clinicians to perform comprehensive evaluations of patients' comorbidities prior to treatment.
Authors
- Rendong Huang (ORCID: https://orcid.org/0000-0002-9383-8157)
- Zheran Liu (ORCID: https://orcid.org/0000-0002-4848-4951)
- Ruidan Li
- Xiaoli Mu
- Xingchen Peng (ORCID: https://orcid.org/0000-0002-7534-4903)
Institutions
- Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1472197
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27